U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07416500) titled 'BRCA1, RASSF1A and PTEN Methylation in Breast Lesions of Uncertain Malignant Potential' on Feb. 10.
Brief Summary: Breast cancer is the most common malignancy in women. In the Slovenian national breast cancer screening program DORA, suspicious breast lesions are further evaluated in diagnostic procedures. Some lesions remain classified as breast lesions of uncertain malignant potential (B3 lesions), which require additional diagnostic assessment because of their variable risk of malignancy.
This prospective interventional study is performed at the Institute of Oncology Ljubljana within the multidisciplinary board for non-palpable b...